6,678 trials
Major Depressive Disorder
Primary: Quick Inventory of Depressive Symptoms — 46.6; 41.8; 46.0 percentage of participants
Medication Adherence · Bipolar Disorder
Primary: Treatment Non-adherence Percentage as Measured by the Tablet Routines Questionnaire (TRQ) — 16.11; 13.88 Percentage of doses
Cholecystectomy, Laparoscopic
Primary: The Percentage of Patients With Optimal Surgical Space Conditions ( 1 at a 4-step Scale) Assessed at the Time During Surgery, When View Was Less — 28; 4 percentage of…
Cervical Pain · Pelvic Pain
Primary: Tenaculum Pain — 12.3; 36.6 mm
Glaucoma · Cataract
Primary: Percent Change in Flare at Resolution — 64.8; 68.3; 65.7 Percent change in flare
Primary Total Hip and Knee Arthroplasty
Primary: Blood Loss — 6; 1 participants
Retinal Vein Occlusions
Primary: Change From Baseline Visual Acuity at 6 Months — 2.3; 0.1 ETDRS score
Relapsing-remitting Multiple Sclerosis
Primary: Number of Days Until First On-study Relapse — NA; 103 days — p=0.125
Tonsillitis · Pain
Primary: Efficacy of Two Different Liquid Pain Medications: Tramadol vs. Codeine/Acetaminophen During the Post-tonsillectomy Recovery Period. — 1.5; 1 days
Influenza
Primary: Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) — 8…
Dilated Cardiomyopathy
Primary: Improvement in Left Ventricular Ejection Fraction — 42.1; 37.6 Percentage — p=0.267
Chronic Total Occlusion
Primary: Composite Rate of Major Adverse Events — 3.3 percentage of participants
Drug Safety
Primary: Subjects Experiencing Discomfort When Undergoing Peripheral Arteriography — 53; 92; 48; 82 participants
Hyperparathyroidism, Secondary · Kidney Failure, Chronic
Primary: Change in Endothelial Cell Function — .23 percent change in FMD
Cystic Fibrosis · Exocrine Pancreatic Insufficiency
Primary: Treatment Difference for Acceptability of Treatment — 1.5; 3.5; 2.5; 1.0 units on a scale